Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells

Cancer Research

Volumn 71, Issue 14, 2011, Pages 4790-4798

  Kitajima, Masayuki ^a,d   Ito, Toshihiro ^a   Tumes, Damon J ^a   Endo, Yusuke ^a   Onodera, Atsushi ^a   Hashimoto, Kahoko ^b   Motohashi, Shinichiro ^a   Yamashita, Masakatsu ^a   Nishimura, Takashi ^c   Ziegler, Steven F ^d   Nakayama, Toshinori ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA INSTITUTE OF TECHNOLOGY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P 15095; GRANZYME B; INTERLEUKIN 4; OVALBUMIN; PERFORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; HELPER CELL; MEMORY CELL; MOLECULAR DYNAMICS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL; TH2 CELL; TUMOR IMMUNOLOGY;

ANIMALS; CELL GROWTH PROCESSES; CYTOTOXICITY, IMMUNOLOGIC; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-4; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASMS, EXPERIMENTAL; TH2 CELLS;

EID: 79960395601     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1572     Document Type: Article

References (49)

1. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000;75:235-82. (Pubitemid 30436846)
2. Bosco M, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L, et al. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 1990;145:3136-43. (Pubitemid 20382591)
3. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992;257:548-51.
4. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994;153:5659-73.
5. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68. (Pubitemid 29028508)
6. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999;190:617-27. (Pubitemid 29428646)
7. Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003;197:387-93. (Pubitemid 36184245)
8. Jamieson BD, Ahmed R. T cell memory. Long-term persistence of virus-specific cytotoxic T cells. J Exp Med 1989;169:1993-2005. (Pubitemid 19162961)
9. Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992;360:264-5.
10. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4. (Pubitemid 44498003)
11. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13. (Pubitemid 36077915)
12. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9. (Pubitemid 44547756)
13. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-46.
14. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009;9:704-16.
15. Kern DE, Klarnet JP, Jensen MC, Greenberg PD. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol 1986;136:4303-10. (Pubitemid 16123088)
16. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702. (Pubitemid 28115185)
17. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46. (Pubitemid 26074503)
18. Nakayama T, Yamashita M. Initiation and maintenance of Th2 cell identity. Curr Opin Immunol 2008;20:265-71.
19. Nakayama T, Yamashita M. Critical role of the Polycomb and Trithorax complexes in the maintenance of CD4 T cell memory. Semin Immunol 2009;21:78-83.
20. Terme M, Tomasello E, Maruyama K, Crépineau F, Chaput N, Flament C, et al. IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. J Immunol 2004;172:5957-66. (Pubitemid 38621195)
21. Yagi H, Deguchi K, Aono A, Tani Y, Kishimoto T, Komori T. Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood 1998;92:108-17. (Pubitemid 28303182)
22. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-8. (Pubitemid 23093629)
23. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, et al. Essential role of Stat6 in IL-4 signalling. Nature 1996;380:627-30. (Pubitemid 26119015)
24. Murphy KM, Heimberger AB, Loh DY. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 1990;250:1720-3. (Pubitemid 120031881)
25. Yamashita M, Hashimoto K, Kimura M, Kubo M, Tada T, Nakayama T. Requirement for p56(lck) tyrosine kinase activation in Th subset differentiation. Int Immunol 1998;10:577-91. (Pubitemid 28221459)
26. Yamashita M, Katsumata M, Iwashima M, Kimura M, Shimizu C, Kamata T, et al. T cell receptor-induced calcineurin activation regulates T helper type 2 cell development by modifying the interleukin 4 receptor signaling complex. J Exp Med 2000;191:1869-79. (Pubitemid 30390350)
27. Yamashita M, Shinnakasu R, Nigo Y, Kimura M, Hasegawa A, Taniguchi M, et al. Interleukin (IL)-4-independent maintenance of histone modification of the IL-4 gene loci in memory Th2 cells. J Biol Chem 2004;279:39454-64. (Pubitemid 39258211)
28. Ohta S, Tsukamoto H, Watanabe K, Makino K, Kuge S, Hanai N, et al. Tumor-associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy. Immunol Lett 1995;44:35-40.
29. + cells by CD4. Science 1990;249:1558-61.
30. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A 1998;95:5690-3. (Pubitemid 28224157)
31. Yamashita M, Kimura M, Kubo M, Shimizu C, Tada T, Perlmutter RM, et al. T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. Proc Natl Acad Sci U S A 1999;96:1024-9. (Pubitemid 29072177)
32. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
33. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992;58:143-75.
34. Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977;25:323-88.
35. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001;13:458-64. (Pubitemid 32728479)
36. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009;9:568-80.
37. Yamashita M, Hirahara K, Shinnakasu R, Hosokawa H, Norikane S, Kimura MY, et al. Crucial role of MLL for the maintenance of memory T helper type 2 cell responses. Immunity 2006;24:611-22. (Pubitemid 43728153)
38. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002;20:323-70. (Pubitemid 34293428)
39. Ullrich E, Bonmort M, Mignot G, Jacobs B, Bosisio D, Sozzani S, et al. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J Immunol 2008;180:7887-97.
40. Katsumoto T, Kimura M, Yamashita M, Hosokawa H, Hashimoto K, Hasegawa A, et al. STAT6-dependent differentiation and production of IL-5 and IL-13 in murine NK2 cells. J Immunol 2004;173:4967-75. (Pubitemid 39387779)
41. Loza MJ, Perussia B. Final steps of natural killer cell maturation: a model for type 1-type 2 differentiation? Nat Immunol 2001;2:917-24.
42. Brady J, Carotta S, Thong RP, Chan CJ, Hayakawa Y, Smyth MJ, et al. The interactions of multiple cytokines control NK cell maturation. J Immunol 2010;185:6679-88.
43. Allavena P, Bianchi G, Paganin C, Giardina G, Mantovani A. Regulation of adhesion and transendothelial migration of natural killer cells. Nat Immunol 1996;15:107-16. (Pubitemid 27100002)
44. Caligiuri MA. Human natural killer cells. Blood 2008;112:461-9.
45. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40. (Pubitemid 33043908)
46. bright NK cells resemble the human CD56bright NK-cell population. Eur J Immunol 2010;40:1428-39.
47. Rodolfo M, Zilocchi C, Accornero P, Cappetti B, Arioli I, Colombo MP. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. J Immunol 1999;163:1923-8. (Pubitemid 29382193)
48. Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 1999;189:803-10. (Pubitemid 29189685)
49. Schuler T, Kammertoens T, Preiss S, Debs P, Noben-Trauth N, Blankenstein T. Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(+) T cells. J Exp Med 2001;194:1767-75. (Pubitemid 34028656)